Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma Multiforme
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for
their growth. Drugs used in chemotherapy, such as temozolomide and carmustine, work in
different ways to stop tumor cells from dividing so they stop growing or die. It is not yet
known whether erlotinib is more effective than temozolomide or carmustine in treating
recurrent glioblastoma multiforme.
PURPOSE: This randomized phase II trial is studying erlotinib to see how well it works
compared to temozolomide or carmustine in treating patients with recurrent glioblastoma
multiforme.
Phase:
Phase 2
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC